Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347740 | 0.81 | CHRM2 (0.37) | — | |
| SCHEMBL13359975 | 0.77 | CHRM2 (0.35) | — | |
| SCHEMBL7769821 | 0.77 | CHRM2 (0.32) | — | |
| SCHEMBL28299190 | 0.73 | — | — | |
| SCHEMBL17886845 | 0.70 | CYP19A1 (0.41) | — | |
| SCHEMBL12757778 | 0.70 | — | — | |
| SCHEMBL1493618 | 0.70 | — | — | |
| SCHEMBL28864982 | 0.70 | RECQL (0.35) | RIPK1 | |
| SCHEMBL14254009 | 0.70 | ELANE (0.42) | RIPK1 | |
| SCHEMBL15498623 | 0.69 | CHRM3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | RIPK1 1537/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | RIPK1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.